News

$VNRX Announces the Initial Sale of its New Nu.Q Research Kits

ISNES, Belgium, Sept. 22, 2017 — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”) today announced its strategy for a new range of Clinical Research Use Only (RUO) kits based on its proprietary Nucleosomics™ technology and the receipt of an order of RUO kits from a large multinational pharmaceutical company.

Chief Executive Officer of Volition, Cameron Reynolds, commented, “This is a very important milestone for Volition as it represents our first revenue from the Nu.Q™ platform. The RUO kits could be used to develop a companion diagnostic to a pharmaceutical company’s therapeutic product, so could represent an additional potential revenue stream beyond the commercialization of our blood-based cancer tests on the same platform of assays. After the initial sale of the RUO kits, a significant licensing arrangement is possible if the assays become a crucial component of another company’s product.”

The RUO kits use the same platform as Volition’s cancer diagnosis panels but may be used for many other purposes, for example as an aid to drug development and treatment selection. This first sale followed a request for a bespoke kit and precedes the launch of the first series of Volition’s products. Volition aims to offer off-the-shelf kits initially with a Total Nucleosome assay in the first quarter of 2018, followed in the second quarter of 2018 by a range of kits initially developed for its own internal cancer diagnostic development programs. The RUO range will allow researchers to explore patterns of epigenetic modifications in circulating nucleosomes across a broad range of clinical applications including cancers, inflammatory and infectious diseases.

Dr. Mark Eccleston, Volition’s Business Development Director, commented, “There has been a lot of interest in collaborating with Volition for evaluating nucleosome profiles in a range of applications beyond our core focus in diagnostics. Our suite of Nu.Q™ RUO assays will provide researchers with a complete solution for profiling cell free nucleosomes from cell to serum. This will raise the profile of our approach and broaden the application base beyond our current focus in cancer. The RUO kits will provide external validation of our technology and an expanded user base. We expect this to lead to future licensing opportunities from new clinical applications of our Nucleosomics™ technology.”

About Volition

Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present.

As cancer screening programs become more widespread, Volition’s products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life.

Volition’s research and development activities are currently centered in Belgium, with additional offices in London, Texas and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.

For more information about Volition, visit Volition’s website (http://www.volitionrx.com)  or connect with us via:

Twitter: https://twitter.com/volitionrx
LinkedIn: http://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx

The contents found at Volition’s website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document.  The addresses for Volition’s website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.

Media / Investor Contacts

Louise Day, Volition

L.day@volitionrx.com

+44 (0)7557 774620

Scott Powell, Volition

S.powell@volitionrx.com

+1 (646) 650 1351

Tirth Patel, Edison Advisors

tpatel@edisongroup.com

+1 (646) 653 7035

Rachel Carroll, Edison Advisors

rcarroll@edisongroup.com

+44 (0)20 3077 5711

Safe Harbor Statement

Statements in this press release may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as “expects,” “anticipates,” “intends,” “plans,” “aims,” “targets,” “believes,” “seeks,” “estimates,” “optimizing,” “potential,” “goal,” “suggests,” “could,” “would,” “should,” “may,” “will” and similar expressions identify forward-looking statements. These forward-looking statements relate to the effectiveness of Volition’s bodily-fluid-based diagnostic tests as well as Volition’s ability to develop and successfully commercialize such test platforms for early detection of cancer. Volition’s actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, if Volition fails to develop and commercialize diagnostic products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition’s failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in Volition’s development pipeline or any other diagnostic products Volition might develop; Volition will face fierce competition and Volition’s intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in Volition’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics®, NuQ®, Nu.Q™ and HyperGenomics® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. Additionally, unless otherwise specified, all references to “$” refer to the legal currency of the United States of America.

Friday, September 22nd, 2017 News Comments Off

$EKSO Appoints Ted Wang to its Board of Directors

RICHMOND, Calif., Sept. 22, 2017 — Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (“Ekso” or “Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today announced the appointment of Ted Wang, PhD. to its Board of Directors, effective immediately.

“Ted’s strong track record of successful strategic, operational, and financial management, combined with his deep knowledge of Ekso’s technology and end markets, make him extremely qualified to help guide our leadership team,” said Thomas Looby, Ekso’s President and Chief Executive Officer.

Dr. Wang is the Chief Investment Officer of Puissance Capital Management, a global asset manager founded in 2015 with offices in the U.S. and China. Puissance was the lead investor in Ekso’s recently completed rights offering.  Prior to founding Puissance, Dr. Wang was a Partner of Goldman Sachs & Co. in New York. During his 18-year tenure at Goldman Sachs he held many leadership positions including as a member of the Goldman Sachs Risk Committee. Prior to joining Goldman Sachs, he co-founded Xeotron Corp., a company specializing in DNA biochips in Texas. Dr. Wang holds a Ph.D. in Physics from the University of Minnesota, an MBA from the University of Texas, Austin, and a BS from Fudan University, China.

Dr. Wang commented, “I am excited to join the Ekso Bionics Board, and I look forward to helping the company realize the potential and promise of its innovative exoskeleton portfolio. Ekso has an extraordinary opportunity to expand its presence in key international markets, and I am committed to working with the Ekso management team to execute on that opportunity.”

Dr. Wang will replace Dan Boren, who joined the Ekso Board in April 2013 and resigned effective September 19, 2017.

“On behalf of management and the entire Board of Directors, I want to thank Dan for his years of service and his role as Chairman of Ekso’s Nominating and Governance Committee,” said Mr. Looby, “We appreciate Dan’s commitment and dedication to the Company.”

About Ekso Bionics

Ekso Bionics is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical, industrial and defense applications. Founded in 2005, the company continues to build upon its unparalleled expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe, to providing research for the advancement of R&D projects intended to benefit U.S. defense capabilities. The company is headquartered in the Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO. For more information, visit: www.eksobionics.com.

Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) estimates or projection of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the Company’s future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain adequate financing to fund the Company’s operations and necessary to develop or enhance our technology, the significant length of time and resources associated with the development of the Company’s products, the Company’s failure to achieve broad market acceptance of the Company’s products, the failure of our sales and marketing organization or partners to market our products effectively, adverse results in future clinical studies of the Company’s medical device products, the failure to obtain or maintain patent protection for the Company’s technology, failure to obtain or maintain regulatory approval to market the Company’s medical devices, lack of product diversification, existing or increased competition, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. To learn more about Ekso Bionics please visit us at www.eksobionics.com. The Company does not undertake to update these forward-looking statements.

Investor Contact:
Matthew Ventimiglia
212-599-1265
investors@eksobionics.com

Media Contact:
Carrie Yamond
917-371-2320
cyamond@lazarpartners.com

Friday, September 22nd, 2017 News Comments Off

$ARDM to Present at the Ladenburg Thalmann 2017 Healthcare Conference on September 26

HAYWARD, Calif.

Aradigm Corporation (Nasdaq:ARDM) (“Aradigm” or the “Company”) today announced that Aradigm management will present at the Ladenburg Thalmann 2017 Healthcare Conference on Tuesday, September 26, 2017, at 2:00 p.m. ET. The event will be held at the Sofitel New York in New York, New York.

Interested parties can access a live audio webcast and slide presentation at www.aradigm.com. An archived presentation will be available on the Company’s Web site for 30 days.

About Aradigm

Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. Aradigm has completed two Phase 3 clinical trials with Linhaliq™, an investigational proprietary formulation of ciprofloxacin for inhalation, for the treatment of NCFBE and submitted a New Drug Application to the FDA for this indication. Aradigm’s inhaled ciprofloxacin formulations, including Linhaliq, are also product candidates for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax.

More information about Aradigm can be found at www.aradigm.com.

Aradigm and the Aradigm Logo are registered trademarks of Aradigm Corporation.

 

Aradigm Corporation
Nancy Pecota, 510-265-8800
Chief Financial Officer

Friday, September 22nd, 2017 News Comments Off

$CIIX NetworkNewsWire Announces Publication on Cannabis Industry Forecasts

NEW YORK, NY–(Sep 22, 2017) – NetworkNewsWire (“NNW”), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring ChineseInvestors.com, Inc. (OTCQB: CIIX), a client of NNW recognizing unprecedented opportunities in the U.S. cannabis industry and laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

The publication is titled, “Cannabinoid Consumer Market Booming as CBD Enjoys Growth in Public Sentiment.” It discusses various cannabis-based public companies determined to expand with the booming cannabis market.

To view the full publication, visit: https://www.networknewswire.com/cannabinoid-consumer-market-booming-cbd-enjoys-growth-public-sentiment/

“Branching out into the unique adaptations of the hemp oil business made perfect business sense for ChineseInvestors.com (CIIX) (www.ChineseInvestors.com), a leading financial information website for Chinese-speaking consumers and investors. CIIX has already established two wholly-owned subsidiaries based in China and the United States. CBD Biotechnology Co., Ltd., located in the free trade zone of Shanghai, China, has plans to deliver a hemp-infused skin care line in China before the end of 2017, while ChineseHempOil.com, Inc., located in the U.S., has launched its first hemp oil product line, ‘OptHemp.’

“While the demand for hemp-based cannabidiol has skyrocketed, so have the number of companies jumping into the market, Marijuana Business Daily reports (http://nnw.fm/7ENhH). There are now hundreds, if not thousands of hemp CBD companies flooding the market looking to take advantage of the profits to be made in the global cannabis industry. For companies like ChineseInvestors.com, which has been in business since 1999, capitalizing on the convergence of CBD and the nutrition and health products market in mainland China was a no-brainer.”

About ChineseInvestors.com

Founded in 1999, ChineseInvestors.com endeavors to be an innovative company providing: (a) real-time market commentary, analysis, and educational related services in Chinese language character sets (traditional and simplified); (b) advertising and public relation related support services; and (c) retail and online sales of hemp-based products and other health related products. For more information visit www.ChineseInvestors.com.

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

NNW Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office

Friday, September 22nd, 2017 News Comments Off

$CIIX Cannabinoid Consumer Market Booming as CBD Enjoys Growth in Public Sentiment

September 21, 2017

NetworkNewsWire Editorial Coverage: Medical cannabis sales are set to impress even the most timid investor, with projected sales of nearly $5 billion in 2017, or about 67% of the $7.2 billion legal cannabis market. Hemp-derived cannabidiol (CBD) product sales are also expected to be a billion-dollar business within three years, growing at a projected 55% compound annual growth rate from 2016’s $170 million in revenue, according to an article in Forbes(1). As the cannabis industry continues to flourish, many publicly traded companies are finding ample opportunities to thrive. Standout companies determined to grow with the industry include ChineseInvestors.com (CIIX) (CIIX Profile), CV Sciences, Inc. (CVSI), Terra Tech Corp. (TRTC), Medical Marijuana, Inc. (MJNA) and Hemp, Inc. (HEMP)

It’s worthwhile to note that significant changes in the acceptance of medical and recreational marijuana also includes the alternative forms of CBD-infused and hemp-derived products, which most people now understand do not contain THC, the psychoactive compound found in marijuana. A massive amount of research into the health benefits of CBD and its effect on mental health disorders is also underway in the scientific community.

Branching out into the unique adaptations of the hemp oil business made perfect business sense for ChineseInvestors.com (CIIX) (www.ChineseInvestors.com), a leading financial information website for Chinese-speaking consumers and investors. CIIX has already established two wholly-owned subsidiaries based in China and the United States. CBD Biotechnology Co., Ltd., located in the free trade zone of Shanghai, China, has plans to deliver a hemp-infused skin care line in China before the end of 2017, while ChineseHempOil.com, Inc., located in the U.S., has launched its first hemp oil product line, “OptHemp.” Customers of ChineseHempOil.com can also purchase the company’s hemp-based products, foods and beverages using bitcoin (http://nnw.fm/w3pbB). The company’s annual financial results, released Tuesday, show a 76% YoY increase in revenues along with an array of new business ventures successfully being introduced to investors.

Among its offerings is the first marijuana social media mobile app designed for Chinese-speaking customers worldwide with a beta version slated for release in November. Its direct-to-consumer e-commerce business is projecting a compound annual growth rate (CAGR) of nearly 100% through FY2020, with revenues reaching $14.8 million. CIIX is positioning itself as a global leader with a goal of becoming the largest Chinese publicly traded company in the legalized CBD market targeting the world’s Chinese-speaking communities (http://nnw.fm/yA6bN).

Another company seeking to make a difference in the rapidly expanding CBD marketplace of cannabis-related products is CV Sciences, Inc. (CVSI), a preeminent supplier and manufacturer of hemp-derived phytocannabinoids including CBD oil. The company plans to exhibit its PlusCBD Oil ™ product brand at the Natural Products Expo East September 14-16 in Baltimore, Maryland. The trade show brings together over 28,000 industry professionals and 1,400 exhibitors. CV Sciences’ product brand is sold at approximately 1,300 health food stores and continues to grow its shelf presence in various retail outlets across the county. In a news release, company spokesman Stuart Tomc said, “It’s evident that hemp-derived CBD products are doing better and growing faster than almost every other category in the supplement industry (http://nnw.fm/H2kId).”

Terra Tech Corp. (TRTC), a vertically integrated, cannabis-focused agriculture company, is also expanding its retail operations. Terra Tech Corp. operates multiple dispensaries as well as cultivation and extraction facilities in California and Nevada. Terra Tech CEO Derek Peterson said the company’s recent acquisition of Tech Center Drive Management LLC, which operates The Reserve OC medical cannabis dispensary in Santa Ana, California, represents another milestone.

“California has emerged as one of the United States’ leading legal cannabis markets, with adult-use planned to come online in 2018,” Peterson said in a news release. “Terra Tech will continue to identify opportunities to expand both its retail and cultivation capabilities in these core markets to drive forward our growth strategy and build value for shareholders (http://cnw.fm/h42vC).”

Medical Marijuana, Inc. (MJNA), the first-ever publicly traded cannabis company in the United States, announced that August 2017 was the company’s largest revenue month in its history. Its wholly owned subsidiaries Kannaway® and HempMeds® Mexico also experienced the best revenue month in their respective histories, Kannaway CEO Blake Schroeder said in a news release (http://cnw.fm/Evae6), noting the company’s plans to launch a series of new products in Q4 2017 as it gears up for its regional convention in Denver, Colorado, this fall. Expansion plans for entering the European market are expected to contribute to the company’s explosive growth, Schroeder added.

Making significant progress in its bid to be known as the world’s number one industrial hemp producer and exporter, HEMP, Inc. (HEMP) has appointed Dr. Robert Ian Bruck, director and founder of the North Carolina State University Environmental Technology Program, as Dean of Hemp, Inc.’s Hemp University. Bruck, who holds two doctorates and years of experience in the fields of plant pathology and ecology, will be responsible for the management and development of curriculum at The Hemp University. Educating not only the public but public policy makers about the business and scientific aspects of industrial hemp – from how to grow it to the many complexities of CBD – is a critical element of moving the cannabis industry forward., according to a company news release (http://cnw.fm/p1hbY).

While the demand for hemp-based cannabidiol has skyrocketed, so have the number of companies jumping into the market, Marijuana Business Daily reports (http://nnw.fm/7ENhH). There are now hundreds, if not thousands of hemp CBD companies flooding the market looking to take advantage of the profits to be made in the global cannabis industry. For companies like ChineseInvestors.com, which has been in business since 1999, capitalizing on the convergence of CBD and the nutrition and health products market in mainland China was a no-brainer.

In a news release (http://nnw.fm/OpHR2), Keevin Gillespie, newly appointed acting president of the company’s ChineseHempOil.com subsidiary, expressed his enthusiasm for the company’s future.

“As the many potential health benefits of hemp continue to be revealed through scientific research and development, I believe the Chinese community will embrace this rediscovered ancient remedy,” Gillespie stated. “I look forward to creating brand awareness and exposure for the Company’s ‘OptHemp’ product line, developing the Company’s network marketing division and generating significant new revenue streams for the Company in the coming year.”

Editorial Sources:
1) Forbes http://nnw.fm/rv2xH

For more on CIIX please visit: ChineseInvestors.com (CIIX) or www.ChineseInvestors.com

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.  The forward-looking statements in this release are made as of the date hereof and NNW undertake no obligation to update such statements.

Thursday, September 21st, 2017 News Comments Off

$MKGI to Present at Third Annual Robins Equity Research Roundup on September 26, 2017

WESTON, FL and PORTLAND, OR–(Sep 21, 2017) – Monaker Group (OTCQB: MKGI), a travel industry technology leader, has been invited to present at the Third Annual Robins Equity Research Roundup, being held on September 26-27, 2017 at the Shilo Inns and Suites in Portland, Oregon. The conference is sponsored by the team at Catalyst Research Management Group, RIA.

Bill Kerby, CEO of Monaker, is scheduled to present on Tuesday, September 26th at 11:15am Pacific time. He will be joined by Richard Marshall, the company’s director of corporate development, for one-on-one meetings with institutional analysts and investors the same day.

The CEO will present its Monaker Booking Engine (MBE), a new cloud-based technology platform that delivers ALR reservations that can be instantly confirmed. As recently announced, the company is nearing the first commercial launch of the cloud-based MBE by a major travel industry partner.

MBE contains over one million instantly-bookable vacation rental properties that are available on nexttrip.com or to other travel businesses using Monaker’s proprietary application program interface (API). The API supports a “white label solution” that allows travel distributors to access and customize vacation rental properties for their website — a unique capability recognized as an industry first.

About Monaker Group

Monaker Group is a technology-driven travel company focused on delivering innovation to alternative lodging rentals (ALR) market. The Monaker Booking Engine (MBE) delivers instant booking of more than 1.4 million vacation rental homes, villas, chalets, apartments, condos, resort residences and castles. MBE offers travel distributors and agencies an industry-first: a customizable, instant-booking platform for alternative lodging. For more information, visit www.monakergroup.com.

Important Cautions Regarding Forward Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties concerning the plans and expectations of Monaker Group. These statements are only predictions and actual events or results may differ materially from those described in this press release due to a number of risks and uncertainties, some of which are out of our control. The potential risks and uncertainties include, among others, or the expectations of future growth may not be realized and the company may not meet applicable NASDAQ Capital Market uplisting requirements and/or may not be approved for uplisting. These forward-looking statements are made only as of the date hereof, and Monaker Group undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are expressly qualified in their entirety by the “Risk Factors” and other cautionary statements included in Monaker Group’s annual, quarterly and special reports, proxy statements and other public filings with the Securities and Exchange Commission (“SEC”), including, but not limited to, the company’s Annual Report on Form 10-K for the period ended February 28, 2017 which has been filed with the SEC and is available at www.sec.gov.

Contact Information

Monaker Group
Richard Marshall – Director of Corporate Development
Tel: (954) 888-9779
rmarshall@monakergroup.com

Investor Relations Contact
Ronald Both or Grant Stude, CMA
Tel (949) 432-7557
MKGI@cma.team

Thursday, September 21st, 2017 News Comments Off

$IGC Readies Line of Medical Dispensary Products Targeting Alzheimer’s Disease

Drug Candidate for Alzheimer’s Shows Promise by Inhibiting Aβ Aggregation without Neuron Damage

BETHESDA, Md., Sept. 18, 2017 – India Globalization Capital, Inc. (NYSE-MKT:IGC) provides an update on compelling in vitro data compiled from genetically engineered cell lines within an Alzheimer’s disease model, showing that at varying concentrations of THC, the aggregation of Aβ protein decreases by as much as 40%.

“As Alzheimer’s progresses, synaptic dysfunction and the death of neurons lead to memory loss. These study results, when combined with the earlier reported data that shows IGC-AD1 reduces Aβ40 and Aβ42 production by as much as 50%, and 40%, without any toxicity, represent a highly significant novel breakthrough that could potentially bring much needed relief from this devastating disease,” states IGC’s CEO Ram Mukunda.

It is believed that a primary cause of AD is the buildup of senile plaque composed of amyloid beta peptides (Aβ plaque) in the cerebral cortex and hippocampus. The key pathogenic event in the onset of AD is Aβ peptide monomers aggregating into prefibrillar oligomers (dimers, trimmers, tetramers and oligomers).  As AD progresses Aβ oligomers directly cause synaptic dysfunction and the death of neurons, consequently leading to a loss of memory.

“A drug that (i) decreases production of Aβ, (ii) inhibits Aβ aggregation into oligomers, (iii) is not toxic to neurons, and (iv) does not cause inebriation (high), could be a powerful weapon against AD and the prevention of AD.  In vitro, our product demonstrates these critical factors and we are pursuing a patent filing that protects this therapy.

AD starts 20 to 25 years before symptoms like memory loss are manifested. Statistically, there is an almost 50% chance of individuals over 80 years contracting AD and over 65% of AD patients are women. Based on the findings of these studies, our plan is two-fold. First, we will position IGC-AD1 as a drug that can be used both as a treatment for AD, and as a prophylactic treatment for the prevention of AD.  Second, we will commercialize a supplement version to be sold as a medical dispensary product.  This will allow our team to work through the FDA approval process for IGC-AD1, while securing market share in the medical dispensary segment. This is a very exciting time for all our shareholders and I look forward to providing updates on our progress in combatting this global disease,” concludes IGC’s CEO Ram Mukunda.

The summary in vitro data indicates that between 2.5nM and 25nM THC concentration, the formation of Aβ1-42 trimers and tetramers in N2aAPP cells are reduced by up to 40% as determined by both fluorescence and immuno blotting assays. Dr. Chuanhai Cao, IGC’s Senior Advisor and Associate Professor of Pharmaceutical Sciences at USF’s College of Pharmacy conducted the studies.

About Alzheimer’s Disease
Alzheimer’s Disease (AD) is a form of dementia.  It is known as America’s most expensive disease, with an estimated cost to the U.S. economy of $236 billion.  AD currently affects more than 5.3 million Americans and over 65% of AD patients are women.  Over the next 20 years, the number of those afflicted with the disease is expected to double.  The forecast is staggering, considering that to date, no effective cure has been found.

About IGC
IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats.  IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA.

For more information please visit www.igcinc.us
Follow us on Twitter @IGCIR and Facebook.com/IGCIR/

Forward-looking Statements
Please see forward looking statements as discussed in detail in IGC’s Form 10K for fiscal year ended March 31, 2017, and in other reports filed with the U.S. Securities and Exchange Commission.

Contact:
Claudia Grimaldi
301-983-0998

Wednesday, September 20th, 2017 News Comments Off